Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309990 | 0.87 | BLM (0.30) | TSHRBLM | |
| SCHEMBL12503609 | 0.79 | NPSR1 (0.42) | NPSR1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL23326947 | 0.78 | NPSR1 (0.40) | NPSR1ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL28263664 | 0.76 | NPSR1 (0.43) | NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27651237 | 0.76 | NPSR1 (0.39) | NPSR1ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL11302273 | 0.76 | NPSR1 (0.39) | NPSR1 | |
| SCHEMBL9414299 | 0.76 | NPSR1 (0.39) | NPSR1ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL2141643 | 0.73 | NPSR1 (0.45) | NPSR1 | |
| SCHEMBL21822831 | 0.71 | NPSR1 (0.39) | NPSR1 | |
| SCHEMBL353640 | 0.69 | TSHR (0.40) | ALDH1A1SMN1; SMN2TSHRUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105193807-A | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING ACUTE MANIA | RICHTER GEDEON NYRT | 2015-12-30 | — | — | CN | claimed |
| CN-104546852-A | (THIO) -CARBAMOYL-CYCLOHEXANE DERIVATIVES AND METHOD FOR TREATING SCHIZOPHRENIA | RICHTER GEDEON NYRT | 2015-04-29 | — | — | CN | claimed |
| CN-101678018-A | (thio) -carbamoyl-cyclohexane derivatives and methods for treating schizophrenia | RICHTER GEDEON NYRT | 2010-03-24 | — | — | CN | claimed |
| CN-101678212-A | Carbamoyl-cyclohexanes for the treatment of acute mania | RICHTER GEDEON NYRT | 2010-03-24 | — | — | CN | claimed |
| EP-0877024-B1 | SUBSTITUTED 6-H-1,3,4-THIADIAZINE-2-AMINES, THE USE THEREOF AS AN AESTHETISING, CARDIOVASCULAR AND HYPOMETABOLIC AGENTS, AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | N T PREDPR LIGAND OBSCHESTVO S (RU) | 2002-02-20 | — | — | EP | claimed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4640216-A1 | SPERMINE DERIVATIVE AND THERAPEUTIC USE THEREOF FOR DISEASES | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2025-10-29 | — | — | EP | disclosed |
| US-4358450-A | FOR DECREASING BLOOD CHOLESTEROL | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-11-09 | — | — | US | disclosed |
| US-4328227-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-05-04 | — | — | US | disclosed |
| US-4289765-A | BRONCHOSPASMOLYTIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-09-15 | — | — | US | disclosed |
| US-4221793-A | ANTIDEPRESSANTS, PSYCHOLOGICAL DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4117004-A | MANUFACTURE OF AMIDOSULFONIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-4117004-A | MANUFACTURE OF AMIDOSULFONIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-4097521-A | Manufacture of amidosulfonic acids | BASF AKTIENGESELLSCHAFT (DT) | 1978-06-27 | — | — | US | disclosed |
| US-4097521-A | Manufacture of amidosulfonic acids | BASF AKTIENGESELLSCHAFT (DT) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | NPSR1 4467/4885ALDH1A1 2476/4885SMN1; SMN2 118/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | NPSR1 4874/4885ALDH1A1 2082/4885SMN1; SMN2 331/4885 |
| US-12583871-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NPSR1 4775/4885ALDH1A1 1190/4885SMN1; SMN2 90/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | NPSR1 4613/4885ALDH1A1 2794/4885SMN1; SMN2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.